Jazz Pharmaceuticals and Nippon Zoki Pharmaceutical said on 21 April 2026 that they had agreed to support the future introduction in Japan of Jazz's cannabidiol epilepsy drug, sold abroad as Epidiolex and Epidyolex. The agreement covered a product not yet launched in Japan, where the 2024 reform had opened a route for approved cannabis-derived medicines.[1]
Listed for context. No score change is recorded for Japan here.
References
- Pharma Japan — Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan22 April 2026; agreement announced 21 April 2026archived
Checked. The date and the event were compared with a source that was read.